Hyoscine-N-Butylbromide

ApprovedSmall molecule

Boehringer Ingelheim

Hyoscine-N-Butylbromide is one of 119 small molecule programs targeting Gastroenteritis. It is currently in Approved.

Indications

Total Trials

Active Trials

118

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastroenteritisActive, not recruiting

Nausea and VomitingActive, not recruiting

Ovarian CancerActive, not recruiting

Cesarean SectionActive, not recruiting

GastroenteritisApproved

Active, not recruiting

Nausea and VomitingApproved

Active, not recruiting

Ovarian CancerPhase 1/Phase 2

Active, not recruiting

Cesarean SectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Femara

Novartis

Phase 3

10 2

Cytoxan

BBaxter Healthcare Corporation

Phase 3

21 3

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 4

Taxotere

AAvyxa

Phase 3

11 5

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 3

4 6

Pamiparib

BeiGene

Phase 3

5 7

Naropin

FFresenius Kabi Oncology Ltd.

Phase 3

1 8

Grafapex

MMedexus Pharma, Inc.

Phase 3

1 9

Hyoscine-N-Butylbromide

Boehringer Ingelheim

Approved

1 10

Carboplatin/paclitaxel

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastroenteritis2 trials

Analgesic Efficacy of Intravenous Hyoscine-N-Butylbromide (HNB) in Abdominal Colic Associated With Acute Gastroenteritis

Unknown status·KKocaeli University·Phase 4·NCT02508142·126 enrolled

Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide

Completed·—·Phase 4·NCT04682860·50 enrolled

Ovarian Cancer1 trial

4FMFES-PET Imaging of Endometrial and Ovarian Cancers

Completed·—·Phase 1/2·NCT04823065·53 enrolled

Cesarean Section1 trial

Efﬁcacy of Hyoscine-n-butylbromide in Catheter-related Bladder Discomfort After Elective Cesarean Section.

Completed·—·N/A·NCT03513250·92 enrolled

Nausea and vomiting1 trial

Hyoscine Butyl-bromide Versus Ondansetron for Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia

Completed·—·Phase 4·NCT04785118·165 enrolled

Endoscopic Retrograde Cholangiopancreatography (ERCP)1 trial

Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)

Completed·—·Phase 3·NCT00731198·650 enrolled

2 more indications

Prospective1 trial

Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02910167·360 enrolled

Prolonged Labor1 trial

Effect Of Intravenous Hyoscine -N-Butyl Bromide In Management Of Prolonged Labor In Nulliparous

Completed·—·N/A·NCT03430362·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Hyoscine-N-Butylbromide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyoscine-N-Butylbromide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyoscine-N-Butylbromide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

Hyoscine-N-Butylbromide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastroenteritis2 trials

Ovarian Cancer1 trial

Cesarean Section1 trial

Nausea and vomiting1 trial

Endoscopic Retrograde Cholangiopancreatography (ERCP)1 trial

Prospective1 trial

Prolonged Labor1 trial

References

Drug Info

Quick Facts

Related News